Get started
Author

Sandra K. Althouse

Observed names: Althouse, Sandra, Althouse, Sandra K., S. Althouse, S. K. Althouse, S.K. Althouse, Sandra K. Althouse, Sandra Althouse, Sandra K Althouse
Observed institutions: Indiana University Health, Brigham and Women's Hospital, Novartis (Switzerland), Memorial Sloan Kettering Cancer Center, Eli Lilly (United States), European Commission, University of Rochester Medicine, Indiana Clinical and Translational Sciences Institute, Dana-Farber Cancer Institute, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, National Cancer Research Institute, Indiana University – Purdue University Indianapolis, Indiana University
ORCID: 0000-0001-6970-2332
Observed ORCID: 0000-0001-6970-2332
OpenAlex ID: A5080410100
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
2017 · N. Adra, L.H. Einhorn, et al. · Annals of Oncology · 196
Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy
2015 · Foster D. Lasley, Edward M. Mannina, et al. · Practical Radiation Oncology · 190
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
2017 · Nabil Adra, Rafat Abonour, et al. · Journal of Clinical Oncology · 180
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
2020 · Greg A. Durm, Salma K. Jabbour, et al. · Cancer · 164
PDF
A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells
2021 · Poornima Bhat-Nakshatri, Hongyu Gao, et al. · Cell Reports Medicine · 115
PDF
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy
2017 · Chunkit Fung, Howard D. Sesso, et al. · Journal of Clinical Oncology · 105
PDF
Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases
2015 · Benjamin D. Goodman, Edward M. Mannina, et al. · Practical Radiation Oncology · 70
Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
2019 · Diane M. Demas, Susan Demo, et al. · Frontiers in Oncology · 66
PDF
40th EASD Annual Meeting of the European Association for the Study of Diabetes
2004 · M. Veitenhansl, K. Stegner, et al. · Diabetologia · 66
Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes
2017 · Edward Michael Mannina, Higinia Rosa Cardenes, et al. · International Journal of Radiation Oncology*Biology*Physics · 59
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
2018 · Greg Andrew Durm, Sandra K. Althouse, et al. · Journal of Clinical Oncology · 51
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014
2016 · N. Adra, S.K. Althouse, et al. · Annals of Oncology · 50
PDF
Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections
2014 · Shaheryar F. Ansari, Bradley N. Bohnstedt, et al. · Journal of Neuro-Oncology · 48
PDF
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC
2021 · Sagar D. Sardesai, Alexandra Thomas, et al. · Clinical Cancer Research · 45
PDF
Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy
2018 · Kevin Shiue, Alberto Cerra-Franco, et al. · Journal of Thoracic Oncology · 45
PDF
Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor
2014 · Ravi P. Sahu, Jesus A. Ocana, et al. · Cancer Research · 45
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors
2018 · Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, et al. · Journal of the National Comprehensive Cancer Network · 35
PDF
TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis
2015 · Susan M. Perkins, Casey Bales, et al. · Breast Cancer Research and Treatment · 35
FAM83A is a potential biomarker for breast cancer initiation
2022 · Natascia Marino, Rana German, et al. · Biomarker Research · 34
PDF
Differences between Supportive Music and Imagery and Music Listening during Outpatient Chemotherapy and Potential Moderators of Treatment Effects
2018 · Debra S Burns, Anthony N Meadows, et al. · Journal of Music Therapy · 33
Providing Quantitative Information and a Nudge to Undergo Stool Testing in a Colorectal Cancer Screening Decision Aid: A Randomized Clinical Trial
2017 · Peter H. Schwartz, Susan M. Perkins, et al. · Medical Decision Making · 33
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
2022 · Milan Radovich, Jeffrey P. Solzak, et al. · Clinical Cancer Research · 30
PDF
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
2022 · Greg Andrew Durm, Hirva Mamdani, et al. · Journal of Clinical Oncology · 29
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029
2022 · Tareq Salous, Nikhil A. Shukla, et al. · Cancer · 28
Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management
2019 · Vaibhav Agrawal, Paul C Dinh, et al. · JNCI Cancer Spectrum · 27
PDF
Works count: 264
Citation count: 2,433
H-index: 26
I10-index: 52
Year
Topic
Type